Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.41 |
| ▸ | BTK | Q06187 | 13/20 | 0.38 |
| ▸ | ITK | Q08881 | 13/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23478962 | 0.87 | MAP3K12 (0.37) | MAP3K12BTKITKPRMT5WDR77 | |
| SCHEMBL23030502 | 0.84 | BTK (0.38) | MAP3K12BTKITKPRMT5WDR77 | |
| SCHEMBL84584 | 0.81 | MET (0.42) | MAP3K12BTKITKPRMT5WDR77 | |
| SCHEMBL13976070 | 0.81 | PRMT5 (0.43) | MAP3K12ITKPRMT5WDR77JAK2 | |
| SCHEMBL84406 | 0.79 | AXL (0.43) | ITKPRMT5WDR77JAK2 | |
| SCHEMBL19105605 | 0.79 | MAP3K12 (0.41) | MAP3K12BTKPRMT5WDR77JAK2 | |
| SCHEMBL18352451 | 0.77 | MAP3K12 (0.35) | MAP3K12 | |
| SCHEMBL91445 | 0.77 | AXL (0.41) | BTKITKPRMT5WDR77JAK2 | |
| SCHEMBL13523638 | 0.76 | MAP3K12 (0.47) | MAP3K12PRMT5WDR77 | |
| SCHEMBL12459687 | 0.76 | KMT2A (0.47) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MAP3K12 1435/4885BTK 3747/4885ITK 4069/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | MAP3K12 1435/4885BTK 3747/4885ITK 4069/4885 |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | NLK, DCLK2, DLK1 | MAP3K12 150/4885BTK 1420/4885ITK 117/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MAP3K12 91/4885BTK 169/4885ITK 1368/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MAP3K12 1441/4885BTK 3812/4885ITK 4073/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | MAP3K12 1441/4885BTK 3812/4885ITK 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.